INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 275 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2022. The put-call ratio across all filers is 0.73 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $3,357 | +7.8% | 49 | +8.9% | 0.00% | – |
| Q1 2024 | $3,114 | -3.4% | 45 | 0.0% | 0.00% | – |
| Q4 2023 | $3,223 | +414.9% | 45 | +275.0% | 0.00% | – |
| Q3 2023 | $626 | -38.3% | 12 | -25.0% | 0.00% | – |
| Q2 2023 | $1,014 | +17.0% | 16 | 0.0% | 0.00% | – |
| Q1 2023 | $867 | +82.1% | 16 | +77.8% | 0.00% | – |
| Q4 2022 | $476 | -88.1% | 9 | -89.0% | 0.00% | -100.0% |
| Q3 2022 | $4,000 | -33.3% | 82 | -26.8% | 0.00% | 0.0% |
| Q2 2022 | $6,000 | +500.0% | 112 | +1144.4% | 0.00% | – |
| Q1 2022 | $1,000 | – | 9 | 0.0% | 0.00% | – |
| Q4 2021 | $0 | – | 9 | +125.0% | 0.00% | – |
| Q3 2021 | $0 | – | 4 | 0.0% | 0.00% | – |
| Q2 2021 | $0 | -100.0% | 4 | -78.9% | 0.00% | – |
| Q1 2021 | $1,000 | – | 19 | +137.5% | 0.00% | – |
| Q3 2020 | $0 | -100.0% | 8 | -61.9% | 0.00% | – |
| Q2 2020 | $1,000 | – | 21 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 375,000 | $15,308,000 | 5.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 113,258 | $4,623,000 | 2.06% |
| Tri Locum Partners LP | 150,783 | $6,155,000 | 2.02% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $2,495,000 | 1.64% |
| Vantage Consulting Group Inc | 226,670 | $9,252,000 | 1.61% |
| Nicholas Investment Partners, LP | 598,261 | $24,421,000 | 1.53% |
| Bellevue Group AG | 3,609,919 | $147,357,000 | 1.44% |
| GENERAL AMERICAN INVESTORS CO INC | 350,804 | $14,320,000 | 1.20% |
| Rhenman & Partners Asset Management AB | 429,728 | $17,541,000 | 1.19% |
| WASATCH ADVISORS LP | 6,506,789 | $265,607,000 | 1.08% |